全文获取类型
收费全文 | 142篇 |
免费 | 5篇 |
国内免费 | 1篇 |
专业分类
基础医学 | 15篇 |
临床医学 | 8篇 |
内科学 | 43篇 |
特种医学 | 6篇 |
外科学 | 8篇 |
综合类 | 1篇 |
预防医学 | 21篇 |
药学 | 2篇 |
肿瘤学 | 44篇 |
出版年
2022年 | 2篇 |
2021年 | 1篇 |
2019年 | 1篇 |
2016年 | 1篇 |
2014年 | 2篇 |
2013年 | 7篇 |
2012年 | 9篇 |
2011年 | 7篇 |
2010年 | 4篇 |
2009年 | 5篇 |
2008年 | 5篇 |
2007年 | 14篇 |
2006年 | 12篇 |
2005年 | 10篇 |
2004年 | 12篇 |
2003年 | 7篇 |
2002年 | 4篇 |
2001年 | 7篇 |
2000年 | 6篇 |
1999年 | 4篇 |
1998年 | 1篇 |
1997年 | 2篇 |
1996年 | 2篇 |
1995年 | 2篇 |
1994年 | 2篇 |
1993年 | 1篇 |
1992年 | 6篇 |
1991年 | 1篇 |
1990年 | 4篇 |
1989年 | 4篇 |
1988年 | 1篇 |
1985年 | 1篇 |
1983年 | 1篇 |
排序方式: 共有148条查询结果,搜索用时 375 毫秒
31.
32.
Nieuwenhuis MH Mathus-Vliegen EM Baeten CG Nagengast FM van der Bijl J van Dalsen AD Kleibeuker JH Dekker E Langers AM Vecht J Peters FT van Dam R van Gemert WG Stuifbergen WN Schouten WR Gelderblom H Vasen HF 《British journal of cancer》2011,104(1):37-42
Background:
The optimal treatment of desmoid tumours is controversial. We evaluated desmoid management in Dutch familial adenomatous polyposis (FAP) patients.Methods:
Seventy-eight FAP patients with desmoids were identified from the Dutch Polyposis Registry. Data on desmoid morphology, management, and outcome were analysed retrospectively. Progression-free survival (PFS) rates and final outcome were compared for surgical vs non-surgical treatment, for intra-abdominal and extra-abdominal desmoids separately. Also, pharmacological treatment was evaluated for all desmoids.Results:
Median follow-up was 8 years. For intra-abdominal desmoids (n=62), PFS rates at 10 years of follow-up were comparable after surgical and non-surgical treatment (33% and 49%, respectively, P=0.163). None of these desmoids could be removed entirely. Eventually, one fifth died from desmoid disease. Most extra-abdominal and abdominal wall desmoids were treated surgically with a PFS rate of 63% and no deaths from desmoid disease. Comparison between NSAID and anti-estrogen treatment showed comparable outcomes. Four of the 10 patients who received chemotherapy had stabilisation of tumour growth, all after doxorubicin combination therapy.Conclusion:
For intra-abdominal desmoids, a conservative approach and surgery showed comparable outcomes. For extra-abdominal and abdominal wall desmoids, surgery seemed appropriate. Different pharmacological therapies showed comparable outcomes. If chemotherapy was given for progressively growing intra-abdominal desmoids, most favourable outcomes occurred after combinations including doxorubicin. 相似文献33.
Nagengast WB Lub-de Hooge MN Oosting SF den Dunnen WF Warnders FJ Brouwers AH de Jong JR Price PM Hollema H Hospers GA Elsinga PH Hesselink JW Gietema JA de Vries EG 《Cancer research》2011,71(1):143-153
Non-invasive imaging of angiogenesis could ease the optimization of antiangiogenesis treatments for cancer. In this study, we evaluated the role of VEGF-PET as a biomarker of dynamic angiogenic changes in tumors following treatment with the kinase inhibitor sunitinib. The effects of sunitinib treatment and withdrawal on the tumor was investigated using the new VEGF-PET tracer (89)Zr-ranibizumab as well as (18)F-FDG PET, and (15)O-water PET in mouse xenograft models of human cancer. The obtained imaging results were compared with tumor growth, VEGF plasma levels and immunohistologic analyzes. In contrast to (18)F-FDG and (15)O-water PET, VEGF-PET demonstrated dynamic changes during sunitinib treatment within the tumor with a strong decline in signal in the tumor center and only minimal reduction in tumor rim, with a pronounced rebound after sunitinib discontinuation. VEGF-PET results corresponded with tumor growth and immunohistochemical vascular- and tumor- markers. Our findings highlight the strengths of VEGF-PET imaging to allow serial analysis of angiogenic changes in different areas within a tumor. 相似文献
34.
Urszula M. Domanska Roeliene C. Kruizinga Wouter B. Nagengast Hetty Timmer-Bosscha Gerwin Huls Elisabeth G.E. de Vries Annemiek M.E. Walenkamp 《European journal of cancer (Oxford, England : 1990)》2013,49(1):219-230
Classical chemotherapeutic anti-cancer treatments induce cell death through DNA damage by taking advantage of the proliferative behaviour of cancer cells. The more recent approach of targeted therapy (usually protein-targeted) has led to many treatments that are currently available or are under development, all of which are designed to strike at the critical driving forces of cancer cells. The interaction of the cancer cells with their microenvironment is one of these fundamental features of neoplasms that could be targeted in such cancer treatments. Haematological and solid tumour cells interact with their microenvironment through membrane chemokine receptors and their corresponding ligands, which are expressed in the tumour microenvironment. Important representatives of this system are the chemokine ligand CXCL12 and its receptor chemokine receptor 4 (CXCR4). This interaction can be disrupted by CXCR4 antagonists, and this concept is being used clinically to harvest haematopoietic stem/progenitor cells from bone marrow. CXCR4 and CXCL12 also have roles in tumour growth and metastasis, and more recently their roles in cancer cell-tumour microenvironment interaction and angiogenesis have been studied. Our review focuses on these roles and summarises strategies for treating cancer by disrupting this interaction with special emphasis on the CXCR4/CXCL12 axis. Finally, we discuss ongoing clinical trials with several classes of CXCR4 inhibitors, and their potential additive value for patients with a (therapy resistant) malignancy by sensitising cancer cells to conventional therapy. 相似文献
35.
Audrey Y. Jung Fränzel J. B. van Duijnhoven Fokko M. Nagengast Akke Botma Renate C. Heine-Bröring Jan H. Kleibeuker Hans F. A. Vasen Jan L. Harryvan Renate M. Winkels Ellen Kampman 《Cancer causes & control : CCC》2014,25(9):1119-1129
Purpose
Dietary intake of B vitamins and methionine, essential components of DNA synthesis and methylation pathways, may influence colorectal tumor (CRT) development. The impact of B vitamins on colorectal carcinogenesis in individuals with Lynch syndrome (LS) is unknown but is important given their high lifetime risk of developing neoplasms. The role of MTHFR C677T genotype in modifying these relationships in LS individuals is also unclear. We investigated associations between dietary intakes of folate, vitamins B2, B6, B12, and methionine and CRT development in a prospective cohort study of 470 mismatch repair gene mutation carriers.Methods
Dietary intakes were assessed by food frequency questionnaire. Cox regression models with robust sandwich covariance estimation, adjusted for age, sex, physical activity, number of colonoscopies during person-time, NSAID use, and mutual vitamins were used to calculate hazard ratios (HRs) and 95 % confidence intervals (95 % CIs). Analyses were also stratified by MTHFR C677T genotype.Results
During a median person-time of 28.0 months, 131 persons developed a CRT. Fifty-one of these persons developed an incident colorectal adenoma, while there were four persons who developed an incident colorectal carcinoma. Compared to the lowest tertile of intake, adjusted HRs (95 % CIs) for CRT development in the highest tertile were 1.06 (0.59–1.91) for folate, 0.77 (0.39–1.51) for vitamin B2, 0.98 (0.59–1.62) for vitamin B6, 1.24 (0.77–2.00) for vitamin B12, and 1.36 (0.83–2.20) for methionine. Low vitamin B2 and low methionine intake were statistically significantly associated with an increased risk of CRT in MTHFR 677TT individuals compared to a combined reference of persons with low intake and CC genotype.Conclusions
There was no suggestion that intake of any dietary B vitamin or methionine was associated with CRT development among those with LS. 相似文献36.
W. H. Peters H. M. Roelofs M. P. Hectors F. M. Nagengast J. B. Jansen 《British journal of cancer》1993,67(6):1413-1417
Glutathione content, enzyme activity and isoenzyme composition of glutathione S-transferases were assayed in normal and Barrett''s esophageal epithelium of ten patients with Barrett''s esophagus. In addition, gastric and duodenal specimens from the same patients were also investigated. Glutathione content, glutathione S-transferase enzyme activity as well as glutathione S-transferase pi content were all significantly lower in Barrett''s epithelium as compared to normal esophageal mucosa. In contrast, glutathione S-transferase class alpha enzymes are markedly expressed in Barrett''s epithelium, whereas only low amounts are present in normal esophageal epithelium. Glutathione and glutathione S-transferase composition in Barrett''s epithelium show striking similarities with gastric epithelium, whereas duodenal epithelium is provided with considerable higher amounts of glutathione and glutathione S-transferases, except for levels of glutathione S-transferase class pi, which are lower. A significant negative correlation exists between glutathione S-transferase enzyme activity in the mucosa along the gastrointestinal tract, and the tumour incidence. Since glutathione and glutathione S-transferase are correlated with protection against cellular or cytogenetic damage, the low content of glutathione and glutathione S-transferases in the Barrett''s esophagus may be a factor of relevance for the increased tumour risk in this tissue. 相似文献
37.
Thijs H. Oude Munnink Maarten A. de Korte Wouter B. Nagengast Hetty Timmer-Bosscha Carolina P. Schröder Johan R. de Jong Guus A.M.S. van Dongen Michael Rugaard Jensen Cornelia Quadt Marjolijn N. Lub-de Hooge Elisabeth G.E. de Vries 《European journal of cancer (Oxford, England : 1990)》2010,46(3):678-684
NVP-AUY922, a potent heat shock protein (HSP) 90 inhibitor, downregulates the expression of many oncogenic proteins, including the human epidermal growth factor receptor-2 (HER2). Because HER2 downregulation is a potential biomarker for early response to HSP90-targeted therapies, we used the 89Zr-labelled HER2 antibody trastuzumab to quantify the alterations in HER2 expression after NVP-AUY922 treatment with HER2 positron emission tomography (PET) imaging.The HER2 overexpressing human SKOV-3 ovarian tumour cell line was used for in vitro experiments and as xenograft model in nude athymic mice. In vitro HER2 membrane expression was assessed by flow cytometry and a radio-immuno assay with 89Zr-trastuzumab. For in vivo evaluation, mice received 50 mg/kg NVP-AUY922 intraperitoneally every other day. 89Zr-trastuzumab was injected intravenously 6 d before NVP-AUY922 treatment and after 3 NVP-AUY922 doses. MicroPET imaging was performed at 24, 72 and 144 h post tracer injection followed by ex-vivo biodistribution and immunohistochemical staining.After 24 h NVP-AUY922 treatment HER2 membrane expression showed profound reduction with flow cytometry (80%) and radio-immuno assay (75%). PET tumour quantification, showed a mean reduction of 41% (p = 0.0001) in 89Zr-trastuzumab uptake at 144 h post tracer injection after NVP-AUY922 treatment. PET results were confirmed by ex-vivo 89Zr-trastuzumab biodistribution and HER2 immunohistochemical staining.NVP-AUY922 effectively downregulates HER2, which can be monitored and quantified in vivo non-invasively with 89Zr-trastuzumab PET. This technique is currently under clinical evaluation and might serve as an early biomarker for HSP90 inhibition in HER2 positive metastatic breast cancer patients. 相似文献
38.
Marloes Berkhout Iris D Nagtegaal Sandra J B Cornelissen Marieke M G Dekkers Fred J J M van de Molengraft Wilbert H M Peters Fokko M Nagengast J Han J M van Krieken Judith W M Jeuken 《Modern pathology》2007,20(12):1253-1262
Primary carcinomas of the small intestine are rare and the mechanism of their pathogenesis is poorly understood. Patients with familial adenomatous polyposis (FAP) have a high risk of developing duodenal carcinomas. The aim of this study is to gain more insight into the development of duodenal carcinomas. Therefore, five FAP-related duodenal carcinomas were characterized for chromosomal and methylation alterations, which were compared to those observed in sporadic duodenal carcinomas. Comparative genomic hybridization (CGH) and methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA) was performed in 10 primary sporadic and five primary FAP-related duodenal carcinomas. In the FAP-related carcinomas, frequent gains were observed on chromosomes 8, 17 and 19, whereas in sporadic carcinomas they occurred on chromosomes 8, 12, 13 and 20. In 60% of the sporadic carcinomas, gains in the regions of chromosome 12 were observed which were absent in the FAP-related carcinomas (P=0.04). Hypermethylation was observed in the immunoglobulin superfamily genes member 4 (IGSF4), TIMP metallopeptidase inhibitor 3 (TIMP3), Estrogen receptor 1 (ESR1), adenomatous polyposis coli (APC), H-cadherin (CDH13) and paired box gene 6 (PAX6) genes. Hypermethylation of PAX6 was only observed in FAP-related carcinomas (3/5) and not in sporadic carcinomas (P=0.02). In conclusion, in contrast to sporadic duodenal carcinomas, gains on chromosome 12 were not observed in duodenal carcinomas of patients with FAP. Identification of the genes in these regions of chromosome 12 could lead to a better understanding of the carcinogenesis pathways leading to sporadic and FAP-related duodenal carcinomas. Furthermore, hypermethylation seems to be a general feature of both FAP-related duodenal carcinomas as well as sporadic duodenal carcinomas with the exception of the PAX6 gene, which is methylated only in FAP-related carcinomas. 相似文献
39.
Vasen HF Möslein G Alonso A Aretz S Bernstein I Bertario L Blanco I Bülow S Burn J Capella G Colas C Engel C Frayling I Friedl W Hes FJ Hodgson S Järvinen H Mecklin JP Møller P Myrhøi T Nagengast FM Parc Y Phillips R Clark SK de Leon MP Renkonen-Sinisalo L Sampson JR Stormorken A Tejpar S Thomas HJ Wijnen J 《Gut》2008,57(5):704-713
40.
Hans F.A. Vasen Mohamed Abdirahman Richard Brohet Alexandra M.J. Langers Jan H. Kleibeuker Mariette van Kouwen Jan Jacob Koornstra Henk Boot Annemieke Cats Evelien Dekker Silvia Sanduleanu Jan–Werner Poley James C.H. Hardwick Wouter H. de Vos tot Nederveen Cappel Andrea E. van der Meulen–de Jong T. Gie Tan Maarten A.J.M. Jacobs Faig Lall A. Mohamed Sijbrand Y. de Boer Paul C. van de Meeberg Fokko M. Nagengast 《Gastroenterology》2010,138(7):2300-2306